New drug OB318 enters human testing for Hard-to-Treat cancers

NCT ID NCT02347228

Terminated Disease control Sponsor: Oneness Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This Phase 1 trial tests an experimental drug called OB318 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and to understand how the body processes the drug. Researchers will also look for early signs that OB318 might slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OB318 capsule
What this could lead to: If OB318 proves safe and shows hints of activity, it could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 21 participants, focused on safety and dosing. The drug may not shrink tumors or improve survival, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES

Contacts and locations

Show contact details

Locations

Taipei Medical University-Shuang Ho Hospital

Taipei, Taiwan
Tri-Service General Hospital

Taipei, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.